Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Virpax Pharmaceuticals ( (VRPX) ).
Virpax Pharmaceuticals has amended its Independent Contractor Agreements with CEO Jatinder Dhaliwal and CFO Usama Chaudhry to align them with their intended structure. These amendments clarify that the services of Mr. Dhaliwal and Mr. Chaudhry are provided through their respective Canadian corporations, Jat Consulting Corp. and Chaudhry U Consulting Inc., and address tax responsibilities and compliance with applicable laws, ensuring proper operational structuring and legal adherence.
More about Virpax Pharmaceuticals
Virpax Pharmaceuticals operates within the pharmaceutical industry, focusing on the development of non-addictive pain management products and treatments for central nervous system disorders. The company aims to advance innovative therapies to enhance the quality of life for patients.
YTD Price Performance: -87.19%
Average Trading Volume: 3,631,412
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.32M
See more insights into VRPX stock on TipRanks’ Stock Analysis page.